Completion of £2 million investment in EMMAC

RNS Number : 4529T
FastForward Innovations Limited
20 March 2019
 

20 March 2019

 

 

FastForward Innovations Ltd

("FastForward", "FFWD" or the "Company")

Completion of £2 million investment in EMMAC Life Sciences Limited, a European medical cannabis company

The Board of AIM-listed FastForward Innovations Limited, trading under the symbol FFWD, is pleased to announce that EMMAC Life Sciences Limited ("EMMAC") has now completed its regulatory filings and that all conditions to FFWD's proposed subscription for 6,666,667 new shares in EMMAC at a price of £0.30 per share for total consideration of £2 million ("Subscription") have now been satisfied and the Subscription has therefore completed.  The £2 million investment gives the Company an approximate 2.6% interest in the issued shares of EMMAC.

 

About EMMAC

 

EMMAC Life Sciences Limited is a European medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production. With supply and distribution partnerships throughout Europe, EMMAC is working to establish itself as both a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp and other derivative products.

 

For further information on EMMAC and its business, operations and investments, as well as its management team, please visit its website at www.emmac.com.

 

Miscellaneous

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information on the Company and its investments please visit www.fstfwd.co or contact:

 

FastForward Innovations Limited

info@fstfwd.co

Lance De Jersey/Chris Bougourd

 

Beaumont Cornish Limited (Nomad)

+44 (0) 207 628 3396

James Biddle/ Roland Cornish

 

Optiva Securities Limited (Broker)

+44 (0) 203 411 1881

Graham Dickson

For further information please visit www.fstfwd.co or contact:

CAUTIONARY STATEMENT

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Fast Forward Innovations assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSEWFSSFUSEID
UK 100

Latest directors dealings